Literature DB >> 7143062

Hemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs.

M F Omojola, A J Fox, R N Auer, F V Viñuela.   

Abstract

A selective non-occlusive technique was developed for administration of BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) into the internal carotid artery of the dog, and the neuropathological effects in the brain were studied. One out of three dogs showed ipsilateral hemorrhagic necrotizing encephalitis at doses of 102 mg/sq m, and all of three dogs showed similar but more severe pathology at doses of 215 to 232 mg/sq m. This study and previous studies in the dog and monkey suggest definite thresholds above which cerebral toxicity occurs when BCNU is administered via the intracarotid route. Greater dilution of drug in the larger territory of supply of the human internal carotid artery allows somewhat higher doses in man. The pathology of the lesion induced by BCNU suggests a primary vascular injury as a pathogenic mechanism, consonant with similar findings following high-dose systemic BCNU administration in man. Investigators conducting ongoing and future trials of intracarotid BCNU in the human for the treatment of intracranial neoplasms should be especially vigilant for a similar toxic effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7143062     DOI: 10.3171/jns.1982.57.6.0791

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

Review 1.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

2.  Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions.

Authors:  S J Hassenbusch; J H Anderson; O M Colvin
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

3.  Delivery of a novel nitrosourea, MCNU, to the brain tissue in glioma-bearing rats. Intracarotid versus intravenous infusion.

Authors:  A Hodozuka; K Sako; H Nakai; M Tomabechi; N Suzuki; Y Yonemasu
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

4.  In vivo measurement of tumor blood oxygenation by near-infrared spectroscopy: immediate effects of pentobarbital overdose or carmustine treatment.

Authors:  R G Steen; K Kitagishi; K Morgan
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas.

Authors:  M S Mahaley; R A Whaley; M Blue; L Bertsch
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

Review 6.  Intracarotid delivery of drugs: the potential and the pitfalls.

Authors:  Shailendra Joshi; Phillip M Meyers; Eugene Ornstein
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

7.  DTI-015 produces cures in T9 gliosarcoma.

Authors:  Dennis Pietronigro; Frank Drnovsky; Humberto Cravioto; Joseph Ransohoff
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

8.  Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.

Authors:  M K Rosenblum; J Y Delattre; R W Walker; W R Shapiro
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.